Home > News > Addressing Potential FCPA Risks in the Pharma and Life Sciences Industries

Addressing Potential FCPA Risks in the Pharma and Life Sciences Industries

Navigant cordially invites you to join our Navigant Exchange roundtable discussion with guest speaker Stuart M. Gerson Esq., former Acting Attorney General of the United States, on the risks and challenges associated with Foreign Corrupt Practices Act (FCPA) in the Pharmaceutical and Life Sciences industries.

Today, the Pharma and Life Sciences industries face unique challenges in meeting FCPA compliance. In industries which are highly regulated and, in many cases, operated by government entities, companies are looking to Congress and regulatory agencies for additional guidance on the FCPA.  More…